Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients

International Journal of Cancer

Volumn 69, Issue 4, 1996, Pages 335-339

  Helle, Svein I ^a   Holly, Jeff M P ^b   Tally, Michael ^c   Hall, Kerstin ^c   Van der Stapfen, Jos ^b   Lønning, Per E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; BREAST NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MIDDLE AGED; POSTMENOPAUSE; PROTEIN PRECURSORS; RADIOIMMUNOASSAY; TAMOXIFEN;

EID: 0029821812     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960822)69:4<335::AID-IJC17>3.3.CO;2-W     Document Type: Article

References (21)

1. BLAT, C., VILLAUDY, J. and BINOUX, M., In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J. clin. Invest., 93, 2286-2290 (1994).
2. COLLETTI, R.B., ROBERTS, J.D., DEVLIN, J.T. and COPELAND, K.C., Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res., 49, 1882-1884 (1989).
3. COULSON, V.J., WASS, J.A.H., ABDULLA, A.F., COTTLRILL, A.M. and HOLLY, J.M.P., Insulin-like growth factor binding proteins (IGFBPs) in acromegaly. Growth Reg., 1, 119-124 (1991).
4. CWYFAN-HUGHES, S.C., WASS. J.A.H. and HOLLY, J.M.P., Two site- specific radioimmunoassays which demonstrate the presence of proteolytically modified insulin-like growth factor-binding protein-3 in circulation. J. Endocrinol., 137, 321-328 (1993).
5. DAVENPORT, M.L., CLEMMONS, D.R., MILES, M.V., CAMACHO-HUBNER, C., D'ERCOLE, A.J. and UNDERWOOD, L.E., Regulation of serum insulin-like growth factor-I (IGF-I) and IGF binding proteins during rat pregnancy. Endocrinology. 127, 1278-1286 (1990).
6. FROST, V.J., HELLE, S.I., LØNNING, P.E., VAN DER STAPPEN, J.W.J. and HOLLY, J.M.P., Effects of treatment with megestrol acetate, aminoglutethimide or formestane on insulin-like growth factor (IGF)-I and -II, IGF-binding proteins and IGFBP-3 protease status in patients with advanced breast cancer. J. clin. endocrinol. Metab., 81, 2216-2221 (1996).
7. HILDING, A., BRISMAR, K., DEGERBLAD, M., THOREN, M. and HALL, K., Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin dependent diabetic patients compared to that in healthy subjects. J. clin. endocrinol. Metab., 80, 2646-2652 (1995).
8. HOLLY, J.M.P., CLAFFEY, D.C.P., CWYFAN-HUGHES, S.C., FROST, V.J. and YATEMAN, M.E., Proteases acting on IGFBPs: their occurrence and physiological significance. Growth Reg., 3, 58-61 (1993).
9. HOSSENLOPP, P., SEGOVIA, B., LASSARRE, C., ROOHANI, M., BREDON, M. and BINOUX, M., Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy. J clin. endocrinol Metab., 71, 797-805 (1990).
10. HUYNH, H.T., TETENES, E., WALLACE, L. and POLLAK, M., In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res., 53, 1727-1730 (1993).
11. JONES, J.I. and CLEMMONS, D.R., Insulin-like growth factors and their binding proteins: biological actions. Endocrine Rev., 16, 3-34 (1995).
12. KAREY, K.P. and SIRBASKU, D.A., Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17β-estradiol. Cancer Res., 48, 4083-4092 (1988).
13. LAHTI, E.I., KNIP, M. and LAATIKAINEN, T.J., Plasma insulin-like growth factor I and its binding protein I and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer, 74, 618-624 (1994).
14. LASSARRE, C. and BINOUX, M., Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology, 134, 1254-1262 (1994).
15. LØNNING, P.E., HAU., K., AAKVAAG, A. and LIEN, E.A., Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein 1 in breast cancer patients. Cancer Res., 52, 4719-4723 (1992a).
16. LØNNING, P.E., LIEN, E.A., LUNDGREN, S. and KVINNSLAND, S., Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin. Pharmacokinet., 22, 327-358 (19926).
17. POLLAK, M, CONSTANTINO, J., POLYCHRONAKOS, C., BLAUER, S.-A., GUYDA, H., REDMOND, C., FISHER, B. and MARGOLESE, R., Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J. nat. Cancer Inst., 82, 1693-1697 (1990).
18. REED, M.J., CHRISTODOULIDES, A., KOISTINEN, R., SÄPPELÄ, M., TEALE, J.D. and GHILCHIK, M.W., The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer. Int. J. Cancer, 52, 208-212 (1992).
19. TALLY, M., ERIKSSON, U., THORÉN, M., BRISMAR, K. and HALL, K., Immunoreactive proinsulin-like growth factor-II in healthy subjects, patients with growth hormone deficiency, and patients with type 1 diabetes: effects of insulin-like growth factor-I and insulin. J. clin. endocrinol. Metab., 79, 1576-1581 (1994).
20. TANNENBAUM, G.S., GURD, W., LAPOINTE, M. and POLLAK, M., Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology, 130, 3395-3401 (1992).
21. ZAPF, J., FUTO, E., PETER, M. and FROESCH, E.R., Can "big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia? J. clin. Invest., 90, 2574-2584 (1992).